" "@en . . "N-{7-[(3-O-carbamoyl-6-deoxy-5-methyl-4-O-methyl-beta-D-gulopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl}-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide"@en . . . . "303-81-1"@en . . "Novobiocina"@en . . . . . . . "Oral bioavailability is negligible."@en . . . . . "For the treatment of infections due to staphylococci and other susceptible organisms"@en . . "Novobiocin"@en . . . "Novobiocine"@en . "6 hours"@en . . . . . . . "Novobiocin"@en . . . "Novobiocin is an aminocoumarin. Aminocoumarins are very potent inhibitors of bacterial DNA gyrase and work by inhibiting the GyrB subunit of the enzyme involved in energy tranduction. Novobiocin as well as the other aminocoumarin antibiotics act as competitive inhibitors of the ATPase reaction catalysed by GyrB."@en . . . . . . "approved"@en . . "Jon Thorson, \"Glycorandomization and Production of Novel Novobiocin Analogs.\" U.S. Patent US20120264924, issued October 18, 2012."@en . . . "An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) [PubChem]"@en . . . "95%"@en . "Novobiocinum"@en . . . " "@en . . . . . "# Vickers AA, Chopra I, O'neill AJ: Intrinsic novobiocin resistance in Staphylococcus saprophyticus. Antimicrob Agents Chemother. 2007 Sep 17;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17876001 # Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS: Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc. 2006 Dec 6;128(48):15529-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17132020 # Singh G, Jayanarayan KG, Dey CS: Novobiocin induces apoptosis-like cell death in topoisomerase II over-expressing arsenite resistant Leishmania donovani. Mol Biochem Parasitol. 2005 May;141(1):57-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15811527 # CORBIN EE, PRIGOT A: Novobiocin; absorption, diffusion, and excretion studies. Antibiot Annu. 1956-1957;:392-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13425410 # DAVID NA, BURGNER PR: Clinical effectiveness and safety of novobiocin. Antibiotic Med Clin Ther. 1956 Apr;2(4):219-29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13303117"@en . "Enteric bacteria and other eubacteria"@en . . . . .